Drug combos could be "practice changing" for advanced breast cancer

12/8/2011 | MSNBC · HealthDay News

Two experimental drug combinations extended survival in women with advanced breast cancer, according to studies presented at the San Antonio Breast Cancer Symposium and published in The New England Journal of Medicine. In one study, women with HER2-positive breast cancer treated with Genentech's Herceptin, chemotherapy and experimental drug pertuzumab lived an average of 18.5 months without recurrence, compared with 12.4 months in the group receiving only Herceptin and chemotherapy. Genentech applied for FDA approval of pertuzumab this week.

View Full Article in:

MSNBC · HealthDay News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Economics & Reimbursement Manager - Transcatheter Heart Valve
Edwards Lifesciences
Irvine, CA
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA